Medigus: Polyrizon Commenced a Pre-Clinical Study Testing Several Formulations of its Bio-Gel for Protection against Coronavi...
April 12 2021 - 8:30AM
Medigus Ltd. (Nasdaq: MDGS), a technology company engaged in
advanced medical solutions and innovative internet technologies,
today announced that Polyrizon Ltd. (which Medigus owns 33.24% of
its share capital), a private company engaged in developing highly
differentiated biological gels for the purpose of protecting
patients against biological threats and external pathogens,
commenced a pre-clinical trial to examine its bio-gel efficacy to
protect against coronavirus infection.
Polyrizon develops an innovative technology,
designed to safely prevent allergens and virus intrusion through
the upper airways and eye cavities. Polyrizon’s technology is
comprised of a bio-gel that is applied topically, and can be
formulated both for wet and dry administration.
Polyrizon plans on testing a number of different
formulations of its highly differentiae biological gel for
protection against coronavirus, and on screening several new
formulations designed to prevent coronavirus from effecting
epithelial cells.
The trial results will provide guidance to
Polyrizon for future regulatory process, as well as refine its
existing formulations, and facilitate in the determination of which
formulation is the most promising.
About Medigus
Medigus is traded on the Nasdaq Capital Market.
To learn more about the company’s advanced technology, please
visit www.medigus.com.
Cautionary Note Regarding Forward Looking
Statements
This press release may contain statements that
are “Forward-Looking Statements,” which are based upon the current
estimates, assumptions and expectations of Medigus’ management and
its knowledge of the relevant market. The company has tried, where
possible, to identify such information and statements by using
words such as “anticipate,” “believe,” “envision,” “estimate,”
“expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,”
“potential,” “will,” “would,” “could,” “should,” “continue,”
“contemplate” and other similar expressions and derivations thereof
in connection with any discussion of future events, trends or
prospects or future operating or financial performance, although
not all forward-looking statements contain these identifying words.
For example, Medigus uses forward looking statements when
describing Polyrizon’s intention on testing a several formulations
of its biological gel for protection against coronavirus,
Polyrizon’s purpose of screening several new formulations and the
implications of the trial results on Polyrizon’s regulatory process
and pathway. These forward-looking statements represent Medigus’
expectations or beliefs concerning future events, and it is
possible that the results described in this press release will not
be achieved. By their nature, Forward-Looking Statements involve
known and unknown risks, uncertainties and other factors which may
cause future results of the Medigus’ activity to differ
significantly from the content and implications of such statements.
Other risk factors affecting Medigus and Polyrizon are discussed in
detail in the Medigus’ filings with the Securities and Exchange
Commission. Forward-Looking Statements are pertinent only as of the
date on which they are made, and Medigus undertakes no obligation
to update or revise any Forward-Looking Statements, whether as a
result of new information, future developments or otherwise.
Neither Medigus nor its shareholders, officers and employees, shall
be liable for any action and the results of any action taken by any
person based on the information contained herein, including without
limitation the purchase or sale of Medigus’ securities. Nothing in
this press release should be deemed to be medical or other advice
of any kind
Contact (for media only)
Oz Adler Chief Financial Officer +972-8-6466-880
ir@medigus.com
Medigus (NASDAQ:MDGS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Medigus (NASDAQ:MDGS)
Historical Stock Chart
From Apr 2023 to Apr 2024